New Age Alpha Advisors LLC Acquires New Stake in Masimo Co. (NASDAQ:MASI)

New Age Alpha Advisors LLC purchased a new position in Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,971 shares of the medical equipment provider's stock, valued at approximately $656,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. National Bank of Canada FI raised its position in shares of Masimo by 195.6% during the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider's stock worth $17,666,000 after purchasing an additional 87,675 shares during the period. Lecap Asset Management Ltd. bought a new position in shares of Masimo in the fourth quarter valued at $1,607,000. Nisa Investment Advisors LLC lifted its stake in shares of Masimo by 16,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock valued at $835,000 after buying an additional 5,022 shares in the last quarter. Trust Point Inc. acquired a new position in shares of Masimo during the fourth quarter valued at about $230,000. Finally, Barclays PLC increased its position in shares of Masimo by 152.6% during the third quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after acquiring an additional 24,137 shares in the last quarter. Institutional investors own 85.96% of the company's stock.

Insider Transactions at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by company insiders.

Remove Ads

Masimo Stock Performance

Shares of MASI traded down $7.97 on Friday, reaching $144.40. 1,161,410 shares of the company's stock traded hands, compared to its average volume of 643,123. The stock's 50 day simple moving average is $173.64 and its two-hundred day simple moving average is $163.02. The stock has a market cap of $7.80 billion, a PE ratio of 99.59 and a beta of 1.04. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, analysts forecast that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler lifted their target price on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Raymond James increased their price target on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Masimo has an average rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.